Skip to main content
Premium Trial:

Request an Annual Quote

Sartorius and ProMetic to Supply, Develop Plasma Protein-Separation Technology

NEW YORK, April 3 (GenomeWeb News) - Sartorius and ProMetic BioTherapeutics, a subsidiary of ProMetic Life Sciences, will jointly supply and develop technology for separate proteins from blood plasma, the companies said today.


ProMetic, based in Montreal, Canada, has been licensing its plasma protein -purification technology to the blood industry. Under the agreement, Sartorius of Göttingen, Germany, will supply licensees of ProMetic's technology with filtration equipment and consumables as a "preferred supplier and technology provider," according to the companies.


In addition, the two partners will co-develop ligand-membrane composites for the isolation of proteins from blood plasma and other sources, based on ProMetic's Mimetic Ligand technology and Sartorius' membrane chromatography technology, Sartobind.


The companies did not disclose financial terms of the agreement.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.